过去一年中添加的文章，按日期排序
[PDF][PDF] Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis
JJ Paik, J Vencovský, C Charles-Schoeman… - morbidity and … - clinexprheumatol.org
15 天前 - … case series and open-label clinical trials in patients with DM; … clinical trials of several
other autoimmune diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, …
other autoimmune diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, …
[HTML][HTML] Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn's Disease in the United Arab Emirates (UAE)
L Alrubaiy, LC Pitsillides, T O'Connor… - … Disorders, 2024 - mdpi.com
23 天前 - … kinase (JAK) inhibitors and IL-12/IL-23 antagonists. All drug … (UAE) based on the
clinical trials reviewed by regulatory … in inflammatory bowel disease: A national study based on …
clinical trials reviewed by regulatory … in inflammatory bowel disease: A national study based on …
[HTML][HTML] Treatment options for refractory ulcerative colitis: Small molecules, big effects
I Marafini, J Roseira, M Duijvestein - United European …, 2024 - ncbi.nlm.nih.gov
83 天前 - … process in inflammatory bowel diseases (… inhibiting intracellular pathways downstream
to cytokine receptors (tofacitinib, filogotinib and upadacitinib), have entered into the clinic …
to cytokine receptors (tofacitinib, filogotinib and upadacitinib), have entered into the clinic …
… -sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn's Disease: Post hoc results from the phase 3b SEQUENCE trial
T Raine, S Danese, S Schreiber, X Gao… - … Crohn's and Colitis, 2024 - academic.oup.com
211 天前 - … interleukin [IL]-23 inhibitor) demonstrated superiority over ustekinumab (UST; IL-12/IL-23
inhibitor) for the ranked secondary endpoints of CS-free clinical remission and CS-free …
inhibitor) for the ranked secondary endpoints of CS-free clinical remission and CS-free …
OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn's disease: Results from the phase 3 VIVID 1 study
211 天前 - … directed anti-IL-12/IL-23 inhibitor from the Phase 3, randomised, double-blind,
double-dummy, active- and PBO-controlled, treat-through (TT) study, VIVID-1 (NCT03926130). …
double-dummy, active- and PBO-controlled, treat-through (TT) study, VIVID-1 (NCT03926130). …
Advances in Inflammatory Bowel Diseases Annual Meeting Abstracts, December 14-16, 2023, Orlando, Florida
L Peyrin-Biroulet, C Chapman, JF Colombel, F Caprioli… - 2023 - journals.lww.com
229 天前 - … study directly compared the efficacy and safety of RZB, a selective IL-23 p19 inhibitor,
and ustekinumab (UST), an IL-12/IL-23 … not directly compared in clinical trials. However, …
and ustekinumab (UST), an IL-12/IL-23 … not directly compared in clinical trials. However, …
S1 risankizumab versus ustekinumab in patients with moderate to severe Crohn's Disease: results from the phase 3B SEQUENCE Trial
L Peyrin-Biroulet, C Chapman… - Official journal of the …, 2023 - journals.lww.com
242 天前 - … study directly compared the efficacy and safety of RZB, a selective IL-23 p19 inhibitor,
and ustekinumab (UST), an IL-12/IL-23 … in Inflammatory Bowel Disease Questionnaire …
and ustekinumab (UST), an IL-12/IL-23 … in Inflammatory Bowel Disease Questionnaire …
Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease
X Cui, Y Teng, Y Hu, Q Li, H Pei, Z Yang - International …, 2024 - Elsevier
252 天前 - … with strong involvement from interferon and/or IL-12/IL-23 in their pathogenesis. This
study … candidates with proven excellent selectivity in several clinical studies. Nevertheless, …
study … candidates with proven excellent selectivity in several clinical studies. Nevertheless, …
Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma
C Chang, G Chen, W Wu, D Chen, S Chen, J Gao… - … Research, 2023 - Springer
275 天前 - … to suppress intestinal inflammation in animal models of inflammatory bowel diseases
via … We hypothesize that IL-25 ameliorates airway neutrophilia via inhibiting macrophage …
via … We hypothesize that IL-25 ameliorates airway neutrophilia via inhibiting macrophage …
Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-) 6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling
A Gesiorowski, J Ettich, J Werner, C Wittich… - Journal of Biological …, 2023 - ASBMB
292 天前 - … Western world develop inflammatory bowel disease (IBD). … failed in the phase II
clinical trial due to non-tolerable side … (hTNFα) or IL-12/IL-23, respectively. Immunoprecipitation …
clinical trial due to non-tolerable side … (hTNFα) or IL-12/IL-23, respectively. Immunoprecipitation …